Subarachnoid Hemorrhage International Trialists data repository (SAHIT).
R Loch Macdonald, Michael D Cusimano, Nima Etminan...
https://pubmed.ncbi.nlm.nih.gov/23295631/Actively Recruiting
Led by The Affiliated Hospital Of Guizhou Medical University · Updated on 2025-09-08
396
Participants Needed
28
Research Sites
N/A
Total Duration
Researchers are evaluating whether injecting nicardipine directly into the cerebrospinal fluid improves outcomes for patients with cerebral vasospasm caused by aneurysmal subarachnoid hemorrhage. This multi-center, prospective, double-blinded, randomized controlled trial compares two methods of delivering nicardipine through extraventricular drainage EVD or lumbar drainage LD. The study aims to determine which approach leads to a better prognosis for affected patients. Participants in the treatment group receive intrathecal nicardipine injections via EVD or LD catheters. The process involves withdrawing 6 ml of cerebrospinal fluid, injecting 4 ml 4 mg of nicardipine hydrochloride, followed by 2 ml of saline, then clamping the catheter for 2 hours. This dosing is done twice daily. The control group undergoes a simulated procedure without receiving the drug. The drainage tubes remain open as clinically needed between doses. During the study, participants are monitored for outcomes using multiple scales, including the Modified Rankin Scale at 90 and 365 days, Glasgow Outcome Score, MMSE, NIH Stroke Scale, and rates of complications like infections or hemorrhage. Safety is assessed through adverse event tracking. Follow-up visits occur up to one year after treatment. The entire study period spans from the start of treatment to long-term outcome evaluations.
CONDITIONS
Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial
G
Guangtang Chen, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Affiliated Hospital Of Guizhou Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 21 days
Participants receive intrathecal nicardipine injections or a simulated procedure twice daily through an extraventricular or lumbar drainage catheter to treat cerebral vasospasm.
Twice daily administration visits
Duration - Up to 12 months
Participants are monitored for safety and recovery, including assessment of neurological outcomes and adverse events.
Visits at approximately 90 days and 365 days after treatment start
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
R Loch Macdonald, Michael D Cusimano, Nima Etminan...
https://pubmed.ncbi.nlm.nih.gov/23295631/Fawaz Al-Mufti, Krishna Amuluru, Nitesh Damodara...
https://pubmed.ncbi.nlm.nih.gov/29801906/Jose G Romano, Alejandro M Forteza, Mauricio Concha...
https://pubmed.ncbi.nlm.nih.gov/11950405/R Loch Macdonald, Axel Rosengart, Dezheng Huo...
https://pubmed.ncbi.nlm.nih.gov/14567598/C M Fisher, J P Kistler, J M Davis
https://pubmed.ncbi.nlm.nih.gov/7354892/Mojtaba Dayyani, Behnam Sadeghirad, James C Grotta...
https://pubmed.ncbi.nlm.nih.gov/35354302/Nicholas Dorsch
https://pubmed.ncbi.nlm.nih.gov/21116906/Brandon Foreman
https://pubmed.ncbi.nlm.nih.gov/27258440/Marianna Pegoli, Jay Mandrekar, Alejandro A Rabinstein...
https://pubmed.ncbi.nlm.nih.gov/25495745/Katja E Wartenberg, J Michael Schmidt, Jan Claassen...
https://pubmed.ncbi.nlm.nih.gov/16521258/The Affiliated Hospital Of Guizhou Medical University
Lead Sponsor